Cancer screening now spends a surprising amount of time interrogating bodily fluids. This is what progress looks like.

A new 2026 study in npj Precision Oncology asked a fairly impolite but useful question: could a urine sample help catch lung cancer early, estimate prognosis, and even hint that the cancer has come back after surgery? The researchers looked at tiny RNA fragments called microRNAs inside urinary extracellular vesicles - basically microscopic membrane bubbles that cells shed like sealed little gossip packets - and then used machine learning to sort cancer from non-cancer cases [1].

The result was strong enough to make people in this field sit up a bit straighter. Which, for biomarker research, is the equivalent of flipping a table.

Tiny molecules, big suspicion

MicroRNAs are short bits of non-coding RNA that help regulate gene activity. Cancer tends to mess with them. That makes them interesting as biomarkers: not because they are magical, but because tumors are sloppy neighbors and leave molecular traces in places they should not. Extracellular vesicles help protect these RNAs as they travel through body fluids, including urine [2,3].

That matters because lung cancer is still the leading cause of cancer death worldwide, and early detection is the whole ballgame. Find it early, and treatment options improve a lot. Find it late, and things get uglier fast. Low-dose CT scans help, but they are not perfect, and the broader liquid-biopsy world has been trying to build less invasive ways to spot trouble sooner [4,5].

What this study actually did

The team analyzed urine from 278 patients with lung cancer and 213 controls without cancer. They used small RNA sequencing to profile microRNAs in urinary extracellular vesicles, then trained a machine-learning model to distinguish the groups [1].

It worked unusually well in this case-control setup. The model reached an AUC of 0.942 in training and 0.941 in testing. In plain English, if you randomly handed the model one cancer sample and one non-cancer sample, it would usually rank the cancer sample as more suspicious. For early-stage lung cancer specifically, sensitivity and specificity in the test set were 88.2% and 87.0% [1]. Those are not casual numbers.

The study also went beyond simple detection. Twelve microRNAs dropped after surgery and then climbed again when recurrence happened. Eleven were linked to recurrence-free survival. The researchers then built a 3-microRNA prognostic panel that separated patients into higher- and lower-risk groups [1].

So this was not just, "Can we find cancer?" It was also, "Can the same molecular signal hang around after the first act and keep being useful?" That is a much more interesting trick.

Why this is a big deal, quietly

Urine is cheap to collect, noninvasive, and unlikely to require a dramatic scheduling saga. If this kind of assay holds up in prospective studies, it could become a practical complement to imaging - maybe helping flag who needs closer follow-up, who might be relapsing, or who deserves a second look before the scan starts an argument.

And the broader field is moving in this direction. Recent reviews describe growing interest in liquid biopsy for lung cancer, including circulating RNAs, extracellular vesicles, and machine-learning-based biomarker panels [2-5]. Other groups have reported circulating miRNA panels for non-small cell lung cancer and even explored exhaled microRNA detection, which is either elegant or very on-brand for lung research [5,6]. The basic idea keeps showing up because it makes clinical sense: cancer sheds signals, and body fluids are easier to sample than organs. A shocking administrative advantage.

The part where we stay normal and do not hype ourselves into orbit

There are real caveats. This was a case-control study, not a real-world screening trial. The authors also note systemic differences between cohorts, including age and sample storage conditions [1]. Those details matter because biomarkers can look brilliant when the comparison groups are too cleanly separated. Biology is messy. Hospitals are messy. Freezers are messy. Sometimes the hardest opponent in machine learning is not the tumor. It is batch effects wearing a fake mustache.

There is also the usual translation problem: a promising biomarker is not automatically a clinic-ready test. It needs prospective validation, standardization, and proof that it improves decisions rather than just generating nice ROC curves for conference slides [2-4].

Still, this paper lands in a sweet spot. It is biologically plausible, clinically relevant, and surprisingly ambitious in trying to cover detection, prognosis, and recurrence monitoring in one shot. If the findings reproduce in broader populations, your future lung cancer check may involve a cup, some sequencing, and a machine-learning model doing pattern recognition in the background like an overcaffeinated lab assistant who never asks for weekends.

References

1. Kiritani A, Mori S, Nojiri T, et al. A noninvasive urinary microRNA-based assay for early detection of lung cancer and its potential application to prognosis and recurrence monitoring: a case-control study. npj Precision Oncology. 2026. DOI: https://doi.org/10.1038/s41698-026-01418-w

2. Metcalf GAD, et al. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. 2024;43:2135-2142. DOI: https://doi.org/10.1038/s41388-024-03076-3

3. Rayamajhi S, Sipes J, Tetlow AL, et al. Extracellular Vesicles as Liquid Biopsy Biomarkers across the Cancer Journey: From Early Detection to Recurrence. Clinical Chemistry. 2024;70(1):206-219. DOI: https://doi.org/10.1093/clinchem/hvad176. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC12374260/

4. Zhu W, Love K, Gray SW, et al. Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions. Clinical Lung Cancer. 2023. DOI: https://doi.org/10.1016/j.cllc.2023.01.006

5. Ren F, Fei Q, Qiu K, et al. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. Journal of Experimental & Clinical Cancer Research. 2024;43:96. DOI: https://doi.org/10.1186/s13046-024-03026-7

6. Vancura A, Radpour R, et al. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC). British Journal of Cancer. 2024;131:1350-1362. DOI: https://doi.org/10.1038/s41416-024-02831-3

Disclaimer: This blog post is a simplified summary of published research for educational purposes. The accompanying illustration is artistic and does not depict actual model architectures, data, or experimental results. Always refer to the original paper for technical details.